Search

Stephen J Reinl

from Sacramento, CA
Age ~57
Get Report
Also known as:
Steve J Reinl, Steven J Reinl, Stephen J Reini, Steve Reini
Phone and address:
943 Piedmont Dr, Sacramento, CA 95822
(916) 442-8181
Related to:
Sara A Krebsbach, 71Doretha Campbell, 47Arlene Hoggard, 80Joseph Montalvo, 88Denis Poirier, 53
Connected to:
Bernice D Reinl, 90Beverly Reinl, 70Wendi M Reinl, 58Steven L Reinlie, 38Diana L Reinmann, 38Samuel N Reinman, 47Ashley M Reinmiller, 27Grace M Reinmiller, 83Marilyn L Reinmuth, 88Robert Reinmuth, 78

Stephen Reinl Phones & Addresses

  • 943 Piedmont Dr, Sacramento, CA 95822 (916) 442-8181 (916) 442-8709
  • Davis, CA
  • 943 Piedmont Dr, Sacramento, CA 95822

Work

Position: Sales Occupations

Education

Degree: Associate degree or higher

Emails

s***[email protected]

Resumes

Resumes

Stephen Reinl Photo 1

Molecular Biologist

View page
Location:
Sacramento, CA
Industry:
Biotechnology
Work:
UC Davis - Davis, CA since Apr 2012
Molecular Biologist
Large Scale Biology Corp. - Vacaville, CA Feb 1992 - Dec 2006
Senior Scientist
UC Davis 1989 - 1992
Post Graduate Researcher
Enseco California Analytical Laboratories - West Sacramento, CA 1988 - 1989
Laboratory Intern
Education:
University of California, Davis 1985 - 1990
Bachelor of Science, Genetics
Skills:
Strategic Planning
Product Development
Microsoft Office
Research
Life Sciences
Stephen Reinl Photo 2

Stephen Reinl

View page

Publications

Us Patents

Production Of Peptides In Plants As Viral Coat Protein Fusions

View page
US Patent:
6660500, Dec 9, 2003
Filed:
Jan 5, 2001
Appl. No.:
09/755836
Inventors:
Thomas H. Turpen - Vacaville CA
Stephen J. Reinl - Sacramento CA
Laurence K. Grill - Vacaville CA
Assignee:
Large Scale Biology Corporation - Vacaville CA
International Classification:
C12N 1562
US Classification:
435 697, 435 701, 4352351, 4353201, 435419, 435468, 536 234, 536 235, 536 2372, 800278, 800288
Abstract:
The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusion proteins of the invention have many uses. Such uses include use as antigens for inducing the production of antibodies having desired binding properties, e. g. , protective antibodies, or for use as vaccine antigens for the induction of protective immunity, including immunity against parasitic infections.

Production Of Peptides In Plants As Viral Coat Protein Fusions

View page
US Patent:
7033835, Apr 25, 2006
Filed:
Apr 7, 1998
Appl. No.:
09/057016
Inventors:
Thomas H. Turpen - Vacaville CA, US
Stephen J. Reinl - Sacramento CA, US
Laurence K. Grill - Vacaville CA, US
Assignee:
Large Scale Biology Corporation - Vacaville CA
International Classification:
C12N 15/83
C12N 15/62
C12N 15/33
C12N 7/01
US Classification:
435468, 435 697, 4352351, 4353201, 536 2372
Abstract:
The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusion proteins of the invention have many uses. Such uses include use as antigens for inducing the production of antibodies having desired binding properties, e. g. , protective antibodies, or for use as vaccine antigens for the induction of protective immunity, including immunity against parasitic infections.

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
7084256, Aug 1, 2006
Filed:
Feb 8, 2002
Appl. No.:
10/067790
Inventors:
Alison A. McCormick - Vacaville CA, US
Stephen J. Reinl - Sacramento CA, US
John A. Lindbo - Vacaville CA, US
Thomas H. Turpen - Vacaville CA, US
Assignee:
Large Scale Biology Corporation - Vacaville CA
International Classification:
C12P 21/08
C07K 16/00
C07K 1/00
C07H 21/04
US Classification:
5303873, 5303871, 5303881, 5303882, 530866, 536 231
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

Creation Of Variable Length And Sequence Linker Regions For Dual-Domain Or Multi-Domain Molecules

View page
US Patent:
7297478, Nov 20, 2007
Filed:
Sep 22, 2000
Appl. No.:
09/667237
Inventors:
Stephen J. Reinl - Sacramento CA, US
John A. Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US
Assignee:
Large Scale Biology Corporation - Vacaville CA
International Classification:
C12Q 1/68
C07H 21/04
US Classification:
435 6, 435DIG 37, 435DIG 47, 536 242
Abstract:
Disclosed are methods and compositions for creating a DNA, RNA or protein molecule with two or more nucleic acid or polypeptide domains, respectively, joined by a linker region. These methods are used to generate random linker libraries of nucleic acids that encode dual-domain or multi-domain polypeptides. The linker regions are characterized by both length and sequence variability.

C-Terminally Truncated Interferon

View page
US Patent:
7915483, Mar 29, 2011
Filed:
Oct 18, 2007
Appl. No.:
11/874607
Inventors:
Stephen J. Reinl - Sacramento CA, US
Gregory P. Pogue - Vacaville CA, US
Assignee:
Biolex Therapeutics, Inc. - Pittsboro NC
International Classification:
C12N 15/82
A01H 5/00
C07H 21/04
US Classification:
800288, 800278, 800280, 800294, 800295, 800298, 536 2352, 435419, 4353201
Abstract:
The invention described herein provides a C-terminally truncated interferon having a deletion of 7, 8, or 9 amino acids and having enhanced biological activity, and the polynucleotides encoding such an interferon. Also provided are methods for producing and using such truncated interferon. In some embodiments, the truncated interferon is produced in a plant.

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
20030039659, Feb 27, 2003
Filed:
Feb 8, 2002
Appl. No.:
10/067892
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US
International Classification:
A61K039/00
C07K014/435
A01H001/00
US Classification:
424/185100, 800/288000, 530/350000
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
20030044417, Mar 6, 2003
Filed:
Mar 31, 2000
Appl. No.:
09/539382
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Menlo Park CA, US
International Classification:
C12P021/06
C12P021/04
A61K039/395
A61K039/40
A61K039/42
A61K039/00
A61K039/38
US Classification:
424/184100, 424/277100, 424/192100, 424/131100, 424/132100, 424/133100, 435/069100, 435/070100, 435/070210
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
20030044420, Mar 6, 2003
Filed:
Feb 8, 2002
Appl. No.:
10/067893
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US
International Classification:
A61K039/00
C07H021/04
C12P021/02
C12N005/06
C07K014/435
C07K016/28
US Classification:
424/185100, 530/350000, 530/388800, 435/069300, 435/325000, 435/320100, 536/023530
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.
Control profile
Stephen J Reinl from Sacramento, CA, age ~57 Get Report